FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to obstetrics and gynecology and can be used for prediction of early preeclampsia in period of 11–13 weeks. That is ensured by determining PlGF (placental growth factor) and sVEGF R1 (soluble vasculoendothelial growth factor receptor-1) at 11–13 weeks of pregnancy, and if PlGF is more than 60 pg/ml in combination with sVEGF R1 more than 2,000 pg/ml, the risk of early preeclampsia is predicted to increase.
EFFECT: method enables early detection of high-risk groups for developing early preeclampsia for timely prevention.
1 cl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING THE RISK OF DEVELOPMENT OF PRE-ECLAMPSIA IN WOMEN OF DIFFERENT SOMATOTYPES | 2018 |
|
RU2679111C1 |
| METHOD OF PREDICTING THE RISK OF PRE-ECLAMPSIA IN PREGNANT WOMEN WITH TYPE 1 DIABETES MELLITUS | 2022 |
|
RU2800717C1 |
| METHOD FOR PREDICTION OF PREECLAMPSIA IN PREGNANT WOMEN SUFFERING FROM PLACENTAL INSUFFICIENCY | 2013 |
|
RU2545760C2 |
| METHOD FOR CHOOSING MANAGEMENT OF PREGNANT WOMEN WITH PLACENTAL INSUFFICIENCY AND FOETAL GROWTH INHIBITION SYNDROME | 2013 |
|
RU2517374C2 |
| METHOD FOR PREDICTING THE RISK OF PREECLAMPSIA IN PREGNANT WOMEN WITH TYPE 1 AND TYPE 2 DIABETES MELLITUS | 2020 |
|
RU2751139C1 |
| METHOD FOR CHOOSING MANAGEMENT APPROACH TO PREGNANT WOMEN WITH PLACENTAL INSUFFICIENCY AND FOETAL GROWTH RETARDATION SYNDROME (FGRS) | 2015 |
|
RU2595884C1 |
| METHOD FOR PREECLAMPSIA DIAGNOSTICS IN PREGNANT WOMEN WITH CHRONIC KIDNEY DISEASE | 2016 |
|
RU2623057C1 |
| METHOD FOR CHOOSING MANAGEMENT APPROACH TO PREGNANT WOMEN WITH MILD ARTERIAL HYPERTENSION | 2011 |
|
RU2477476C1 |
| METHOD FOR CHOOSING MANAGEMENT APPROACH TO PREGNANT WOMEN WITH MODERATE PREECLAMPSIA | 2011 |
|
RU2477481C1 |
| METHOD FOR PREDICTION OF PLACENTAL INSUFFICIENCY IN SECOND HALF OF PREGNANCY IN CMV-SEROPOSITIVE WOMEN WITH THREAT OF EARLY MISCARRIAGE | 2017 |
|
RU2691935C2 |
